SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-24-009020 to FOXO TECHNOLOGIES INC. (FOXO)

FOXO TECHNOLOGIES INC.
Date: Aug. 7, 2024 · CIK: 0001812360 · Accession: 0000000000-24-009020

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 001-39783

Date
August 7, 2024
Author
Mark White
Form
UPLOAD
Company
FOXO TECHNOLOGIES INC.

Letter

August 7, 2024 Mark White Interim Chief Executive Officer FOXO Technologies Inc. 729 N. Washington Ave., Suite 600 Minneapolis, MN 55401 Re:FOXO Technologies Inc. Preliminary Proxy Statement on Schedule 14A Filed July 31, 2024 File No. 001-39783 Dear Mark White: We have reviewed your filing and have the following comment. Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe a comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this letter, we may have additional comments. Preliminary Proxy Statement on Schedule 14A filed July 31, 2024 General We note that Proposal 5 of your proxy statement seeks the authorization of the issuance of 20% or more of your outstanding common stock in connection with the acquisition of Myrtle Recovery Centers, Inc. We also note that you are seeking stockholder approval of the potential issuance of shares of common stock in connection with the acquisition of Rennova Community Health, Inc. pursuant to Proposal 6 of your proxy statement. As it appears that Proposals 5 and 6 involve solicitations of your shareholders for the purpose of issuing additional shares which are to be used to acquire other specified companies, and your shareholders will not have separate opportunities to vote upon these transactions, please revise your disclosure to provide the information required by Note A of Schedule 14A for each proposal, including the information set forth in Items 11, 13 and 14 of Schedule 14A, or provide us your analysis why this information is not required. When providing this disclosure, please include the amount of securities to be issued, all audited and pro forma financial information required by Items 13 and 14 of Schedule 14A, and all transaction-related information required by Item 14 of Schedule 14A. Additionally, please file the amended proxy statement with the PREM14A EDGAR tag and ensure that any 1.

August 7, 2024 Page 2 subsequent proxy statement filings are properly designated. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jane Park at 202-551-7439 or Abby Adams at 202-551-6902 with any other questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc:Brian Higley, Esq.

Show Raw Text
August 7, 2024
Mark White
Interim Chief Executive Officer
FOXO Technologies Inc.
729 N. Washington Ave., Suite 600
Minneapolis, MN 55401
Re:FOXO Technologies Inc.
Preliminary Proxy Statement on Schedule 14A
Filed July 31, 2024
File No. 001-39783
Dear Mark White:
            We have reviewed your filing and have the following comment.
            Please respond to this letter within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe a
comment applies to your facts and circumstances, please tell us why in your response.
            After reviewing your response to this letter, we may have additional comments.
Preliminary Proxy Statement on Schedule 14A filed July 31, 2024
General
We note that Proposal 5 of your proxy statement seeks the authorization of the issuance of
20% or more of your outstanding common stock in connection with the acquisition of
Myrtle Recovery Centers, Inc. We also note that you are seeking stockholder approval of
the potential issuance of shares of common stock in connection with the acquisition of
Rennova Community Health, Inc. pursuant to Proposal 6 of your proxy statement. As it
appears that Proposals 5 and 6 involve solicitations of your shareholders for the purpose
of issuing additional shares which are to be used to acquire other specified companies,
and your shareholders will not have separate opportunities to vote upon these transactions,
please revise your disclosure to provide the information required by Note A of Schedule
14A for each proposal, including the information set forth in Items 11, 13 and 14 of
Schedule 14A, or provide us your analysis why this information is not required. When
providing this disclosure, please include the amount of securities to be issued, all audited
and pro forma financial information required by Items 13 and 14 of Schedule 14A, and all
transaction-related information required by Item 14 of Schedule 14A. Additionally, please
file the amended proxy statement with the PREM14A EDGAR tag and ensure that any 1.

August 7, 2024
Page 2
subsequent proxy statement filings are properly designated.
            We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
            Please contact Jane Park at 202-551-7439 or Abby Adams at 202-551-6902 with any
other questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc:Brian Higley, Esq.